Original Publication Date: 1 July, 2015
Publication / Source: Breast Cancer Management
Authors: Suzana C Teixeira, Marie-Jeanne TFD Vrancken Peeters et al
Modalities that are conventionally used for regional and distant metastases staging, in clinical stage II/III breast cancer patients (ultrasonography, computed tomography [CT], MRI and bone scan), may underestimate the spread of the disease. The 18-fluoro-deoxy-glucose whole body PET with CT (18F-FDG PET/CT) is able to more accurately visualize the number of axillary lymph node metastases, the internal mammary chain, periclavicular lymph node metastases and distant disease than the previously mentioned modalities.